- 131. A method according to Claim 129 wherein said alkylating agent anti-cancer agent is selected from the group consisting of mechlorethamine, mitomycin-C, dactinomycin, and mithramycin.
- 132. A method according to Claim 129 wherein said anti-cancer agent is a vinca alkaloid.
- 133. A method according to Claim 132 wherein said vinca alkaloid anti-cancer agent is selected from the group consisting of vincristine, vinblastine, vinorelbine, and vindesine.
- 134. A method according to Claim 129 wherein said taxane anti-cancer agent is selected from the group consisting of paclitaxel and docetaxel.
- 135. A method according to Claim 128 wherein said vesicant anti-cancer agent is administered by inhalation as an aerosolized liquid, powder or gas.
- 136. A method according to Claim 135 wherein said aerosolized vesicant anticancer agent is administered as an aerosolized liquid.
- 137. A method according to Claim 135 wherein said aerosolized anthracycline is administered as an aerosolized powder.
- 138. A method according to Claim 132 wherein said vinca alkaloid anti-cancer agent is administered at a dosage of from about 0.1 mg/m² body surface area to about 90.0 mg/m² body surface area.
- 139. A method according to Claim 138 wherein said vinca alkaloid anti-cancer agent is vincristine and wherein said agent is administered at a dosage of about 1.4 mg/m² body surface area.
- 140. A method according to Claim 138 wherein said vinca alkaloid anti-cancer agent is vinblastine and wherein said agent is administered at a dosage of about 6.0 mg/m² body surface area.
- 141. A method according to Claim 138 wherein said vinca alkaloid anti-cancer agent is vinorelbine and wherein said agent is administered at a dosage of about 30.0 mg/m² body surface area.
- 142. A method according to Claim 138 wherein said vinca alkaloid anti-cancer agent is vindesine wherein said agent is administered at a dosage of about 3.0 mg/m² body surface areas.
- 143. A method according to Claim 129 wherein said taxane anti-cancer agent is administered at a dosage of from about 10.0 mg/m2 body surface area to about 400.0 mg/m² body surface area.